93 related articles for article (PubMed ID: 30789411)
1. Effects of Social and Contextual Factors Including Marital Status and Children on the Use of Palliative Chemotherapy in Metastatic Colorectal Cancer.
Ahmed S; Baig T; Iqbal N; Le D; Chalchal H; Zaidi A; Pahwa P
Am J Clin Oncol; 2019 Apr; 42(4):363-366. PubMed ID: 30789411
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of the Use of Systemic Therapy in Stage IV Colorectal Cancer: Who Gets Chemotherapy?
Ahmed S; Pahwa P; Fields A; Chandra-Kanthan S; Iqbal N; Zaidi A; Reeder B; Plaza FA; Zhu T; Leis A
Oncology; 2015; 88(5):289-97. PubMed ID: 25592112
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
[TBL] [Abstract][Full Text] [Related]
4. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience.
Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A
Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732
[TBL] [Abstract][Full Text] [Related]
5. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study.
Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P
Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180
[TBL] [Abstract][Full Text] [Related]
7. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?
Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS
ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886
[TBL] [Abstract][Full Text] [Related]
8. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
9. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
10. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer.
Chiang CL; Choi HC; Lam KO; Chan BY; Lee SF; Yeung SY; Lau KS; Chan SY; Choy TS; Yuen KK
Asia Pac J Clin Oncol; 2019 Mar; 15 Suppl 2():5-13. PubMed ID: 30887726
[TBL] [Abstract][Full Text] [Related]
12. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
[TBL] [Abstract][Full Text] [Related]
13. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
Sorbye H; Pfeiffer P; Cavalli-Björkman N; Qvortrup C; Holsen MH; Wentzel-Larsen T; Glimelius B
Cancer; 2009 Oct; 115(20):4679-87. PubMed ID: 19562777
[TBL] [Abstract][Full Text] [Related]
15. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
16. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
17. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
18. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
